[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Panafina, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100522297","phase-2-a-study-to-evaluate-the-safety-and-efficacy-of-a-single-dose-of-rabi-767-in-participants-with-acute-pancreatitis-100522297",false,"NCT06080789","A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis","A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis","Key Inclusion Criteria:\n\n* Diagnosis of acute pancreatitis\n* Predicted severe acute pancreatitis, based on protocol defined criteria\n* Lack of clinically meaningful improvement from status at admission, at the discretion of Investigator, at the time of randomization\n* Suitable for EUS-guided study drug administration procedure\n* Contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) of the abdomen\u002Fpancreas available for the evaluation of exclusion criteria\n\nKey Exclusion Criteria:\n\n* Confirmed severe acute pancreatitis as defined by the Revised Atlanta Classification of Acute Pancreatitis (ie, Persistent \\[\\> 48 hours\\] organ failure, per Modified Marshall Score), prior to randomization\n* Anticipated discharge from hospital within 48 hours of randomization\n* More than 30% pancreatic necrosis on screening CECT or MRI\n* History of previous pancreatic necrosis, including necrosectomy\n* History of calcific chronic pancreatitis\n* Evidence of cholangitis","ALL","18 Years","85 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.\n\nThe main question the study aims to answer is:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.\n\nThe study also aims to answer:\n\n• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.\n\nStudy participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.\n\nThe study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.",[27],"Acute Pancreatitis","RECRUITING","2026-05-26",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2024-06-28",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Panafina, Inc.","INDUSTRY",16,""]